Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study

被引:33
作者
Basler, L. [1 ]
Andratschke, N. [1 ]
Ehrbar, S. [1 ]
Guckenberger, M. [1 ]
Tanadini-Lang, S. [1 ]
机构
[1] Univ Zurich, Univ Hosp Zurich, Dept Radiat Oncol, Ramistr 100, CH-8091 Zurich, Switzerland
来源
RADIATION ONCOLOGY | 2018年 / 13卷
关键词
Immunotherapy; Modelling; Treatment planning; Stereotactic body radiotherapy (SBRT); Abscopal effect; ADVANCED PANCREATIC ADENOCARCINOMA; T-CELL TRAFFICKING; DENDRITIC CELLS; LOCAL RADIOTHERAPY; CANCER-IMMUNOTHERAPY; RADIATION-THERAPY; BODY IRRADIATION; GROWTH-FACTOR; IMMUNE CELLS; SOLID TUMORS;
D O I
10.1186/s13014-018-0952-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Tumor immune-evasion and associated failure of immunotherapy can potentially be overcome by radiotherapy, which however also has detrimental effects on tumor-infiltrating and circulating lymphocytes (CL). We therefore established a model to simulate the radiation-dose delivered to CL. Methods: A MATLAB-model was established to quantify the CL-dose during SBRT of liver metastases by considering the factors: hepatic blood-flow, -velocity and transition-time of individual hepatic segments, as well as probability-based recirculation. The effects of intra-hepatic tumor-location and size, fractionation and treatment planning parameters (VMAT, 3DCRT, photon-energy, dose-rate and beam-on-time) were analyzed. A threshold dose >= 0.5Gy was considered inactivating CL and CL0.5 (%) is the proportion of inactivated CL. Results: Mean liver dose was mostly influenced by treatment-modality, whereas CL0.5 was mostly influenced by beam-on-time. 3DCRT and VMAT (10MV-FFF) resulted in lowest CL0.5 values of 16 and 19%. Metastasis location influenced CL0.5, with a mean of 19% for both apical and basal and 31% for the central location. PTV-volume significantly increased CL0.5 from 27 to 67% (10MV-FFF) and from 31 to 98% (6MV-FFF) for PTV-volumes ranging from 14cm(3) to 268cm(3). Conclusion: A simulation-model was established, quantifying the strong effects of treatment-technique, tumor-location and tumor-volume on dose to CL with potential implications for immune-optimized treatment-planning in the future.
引用
收藏
页数:8
相关论文
共 54 条
[1]  
ANDERSON RE, 1977, AM J PATHOL, V89, P367
[2]   Immunobiology of dendritic cells [J].
Banchereau, J ;
Briere, F ;
Caux, C ;
Davoust, J ;
Lebecque, S ;
Liu, YT ;
Pulendran, B ;
Palucka, K .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+
[3]   Radiation oncology in the era of precision medicine [J].
Baumann, Michael ;
Krause, Mechthild ;
Overgaard, Jens ;
Debus, Juergen ;
Bentzen, Soren M. ;
Daartz, Juliane ;
Richter, Christian ;
Zips, Daniel ;
Bortfeld, Thomas .
NATURE REVIEWS CANCER, 2016, 16 (04) :234-249
[4]   Impact of localized radiotherapy on blood immune cells counts and function in humans [J].
Belka, C ;
Ottinger, H ;
Kreuzfelder, E ;
Weinmann, M ;
Lindemann, M ;
Lepple-Wienhues, A ;
Budach, W ;
Grosse-Wilde, H ;
Bamberg, M .
RADIOTHERAPY AND ONCOLOGY, 1999, 50 (02) :199-204
[5]   Immunological interactions in radiotherapy-opening a new window of opportunity [J].
Bhattacharyya, Tapesh ;
Purushothaman, Kiran ;
Puthiyottil, Sanudev Sadanandan Vadakke ;
Bhattacharjee, Atanu ;
Muttah, Geetha .
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (03)
[6]   Effects of Low-Dose Radiation on the Immune System of Mice after Total-Body Irradiation [J].
Bogdandi, Enikoe Noemi ;
Balogh, Andrea ;
Felgyinszki, Nikolett ;
Szatmari, Tuende ;
Persa, Eszter ;
Hildebrandt, Guido ;
Safrany, Geza ;
Lumniczky, Katalin .
RADIATION RESEARCH, 2010, 174 (04) :480-489
[7]   Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer [J].
Campian, Jian L. ;
Sarai, Guneet ;
Ye, Xiaobu ;
Marur, Shanthi ;
Grossman, Stuart A. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (12) :1747-1753
[8]   A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab [J].
Chandra, Ravi A. ;
Wilhite, Tyler J. ;
Balboni, Tracy A. ;
Alexander, Brian M. ;
Spektor, Alexander ;
Ott, Patrick A. ;
Ng, Andrea K. ;
Hodi, F. Stephen ;
Schoenfeld, Jonathan D. .
ONCOIMMUNOLOGY, 2015, 4 (11)
[9]   A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma [J].
Crocenzi, Todd ;
Cottam, Benjamin ;
Newell, Pippa ;
Wolf, Ronald F. ;
Hansen, Paul D. ;
Hammill, Chet ;
Solhjem, Matthew C. ;
To, Yue-Yun ;
Greathouse, Amy ;
Tormoen, Garth ;
Jutric, Zeljka ;
Young, Kristina ;
Bahjat, Keith S. ;
Gough, Michael J. ;
Crittenden, Marka R. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[10]   Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival [J].
Delyon, J. ;
Mateus, C. ;
Lefeuvre, D. ;
Lanoy, E. ;
Zitvogel, L. ;
Chaput, N. ;
Roy, S. ;
Eggermont, A. M. M. ;
Routier, E. ;
Robert, C. .
ANNALS OF ONCOLOGY, 2013, 24 (06) :1697-1703